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Defective Hippo/YAP signaling in the liver results in
tissue overgrowth and development of hepatocellu-
lar carcinoma (HCC). Here, we uncover mechanisms
of YAP-mediated hepatocyte reprogramming and
HCC pathogenesis. YAP functions as a rheostat in
maintaining metabolic specialization, differentiation,
and quiescence within the hepatocyte compartment.
Increased or decreased YAP activity reprograms
subsets of hepatocytes to different fates associated
with deregulation of the HNF4A, CTNNB1, and E2F
transcriptional programs that control hepatocyte
quiescence and differentiation. Importantly, treat-
ment with small interfering RNA-lipid nanoparticles
(siRNA-LNPs) targeting YAP restores hepatocyte
differentiation and causes pronounced tumor regres-
sion in a genetically engineered mouse HCC model.
Furthermore, YAP targets are enriched in an aggres-
sive human HCC subtype characterized by a prolifer-
ative signature and absence of CTNNB1 mutations.
Thus, our work reveals Hippo signaling as a key
regulator of the positional identity of hepatocytes,
supports targeting of YAP using siRNA-LNPs as
a paradigm of differentiation-based therapy, and
identifies an HCC subtype that is potentially respon-
sive to this approach.1692 Cell Reports 10, 1692–1707, March 17, 2015 ª2015 The AuthorINTRODUCTION
Hepatocellular carcinoma (HCC) is the second most common
cause of cancer-related deaths worldwide, and the incidence
is increasing in the United States (El-Serag, 2011; Forner et al.,
2012). Curative resection or transplantation is only possible in
30% of patients, and for advanced HCC, the multi-kinase in-
hibitor sorafenib remains the only approved agent with modest
survival benefits (Cheng et al., 2009; Llovet et al., 2008).
Genomic studies have classified HCC into subsets with distinct
molecular and clinical features (Chiang et al., 2008; Guichard
et al., 2012; Hoshida et al., 2009; Lachenmayer et al., 2012). Acti-
vating CTNNB1 mutations are the most common oncogenic
drivers (being present in 30% of tumors) and define an HCC
subtype characterized by a hepatocyte-like gene-expression
signature, well-differentiated histology, and improved survival.
The other recurrent genetic alterations in HCC involve tumor-
suppressor inactivation (Fujimoto et al., 2012; Guichard et al.,
2012) and have not pointed to readily targetable vulnerabilities.
Thus, there is a need to more fully discern biologically distinct
HCC subtypes and to identify therapeutic targets.
Hippo signaling is an important tumor-suppressor mechanism
in multiple tissues, including the liver (Harvey et al., 2013; Mo
et al., 2014). The core of the pathway involves a kinase cascade
with the homologousMST1 andMST2 (STK3 and STK4) proteins
as upstream kinases that subsequently activate the LATS1/
LATS2 kinases (Yu and Guan, 2013). Signaling inputs include
G protein-coupled receptors, Rho GTPases, AMPK, and polarity
complex proteins such as NF2, AMOT, and a-CATENIN, whichs
link Hippo activity to a variety of cues, including cell contact,
mitotic failure, nutrients, and growth factors (Ganem et al.,
2014; Yu and Guan, 2013). Major downstream targets are the
transcriptional co-activators YAP and TAZ, which are phosphor-
ylated by LATS1/LATS2, leading to their cytoplasmic retention
and degradation. YAP and TAZ promote growth, survival, and/or
stem cell-like phenotypes in many cellular contexts (Mo et al.,
2014), although the key mediators of these processes are not
clearly established.
In the adult mouse liver, inactivation of Mst1/Mst2, Sav1,
or Nf2, or ectopic expression of Yap results in expansion of
atypical ductal cells (ADCs, or ‘‘oval cells’’), liver enlargement,
and progression to HCC or mixed HCC/cholangiocarcinoma,
and Mst1/Mst2 KO or Yap overexpression also causes hepato-
cyte overproliferation (Camargo et al., 2007; Dong et al., 2007;
Lee et al., 2010; Lu et al., 2010; Yimlamai et al., 2014; Zender
et al., 2006; Zhou et al., 2009). Lineage tracing in Yap transgenic
andNf2KO livers indicates that ADCs are derived from de-differ-
entiation of hepatocytes (Yimlamai et al., 2014), consistent with
emerging data demonstrating plasticity of these cells (Schaub
et al., 2014; Yanger et al., 2014), and pointing to important func-
tions of Hippo/YAP in controlling liver cell fate. Consistent with a
role for activated YAP in human HCC, 50% of these tumors
exhibit nuclear YAP staining, and nuclear YAP levels correlate
with decreased survival after resection (Tschaharganeh et al.,
2013; Xu et al., 2009).
Here, we sought to explore the role of YAP in HCC progression
and maintenance in order to define its downstream oncogenic
program, assess its potential as a therapeutic target, and estab-
lish biomarkers to identify the subsets of HCC in which YAP
targeting may be beneficial. By using genetic approaches and
small interfering RNA-lipid nanoparticle (siRNA-LNP) technology
in genetically engineeredmouse (GEM) models, we demonstrate
that activation of endogenous YAP perturbs hepatocyte dif-
ferentiation and maintains this state in advanced tumors.
Correspondingly, YAP silencing in HCC restores hepatocyte dif-
ferentiation and leads to tumor regression. These results provide
a proof-of-concept that differentiation therapy has potential as a
treatment strategy for epithelial tumors.Moreover, the significant
responses induced by siYAP-LNPs support ongoing clinical
development of this therapeutic modality. Finally, our work
shows that an aggressive subtype of human HCC, enriched for
cell-cycle gene expression and lacking CTNNB1 mutations, ex-
hibits a YAP activation signature, pointing to biomarkers to guide
the deployment of YAP-directed therapies in clinical trials.
RESULTS
Role of YAP Downstream of MST1/MST2 in Controlling
Hepatocyte Identity
To begin to explore the relationship between Hippo pathway ac-
tivity and liver cell differentiation, we examined Yap expression
in normal mouse liver. The bile ducts showed strong nuclear
YAP staining (Figures 1A and 1B), consistent with prior obser-
vations (Yimlamai et al., 2014). We also observed a graded
staining pattern in the hepatocyte compartment, with the
periportal hepatocytes (adjacent to the bile duct) showing
readily detectable Yap nuclear and cytoplasmic localization,Celland with pericentral hepatocytes (adjacent to the central vein)
showing clear nuclear exclusion. SOX9, which like YAP is a
marker of bile ducts and liver cell plasticity (Antoniou et al.,
2009; Shin et al., 2011; Yanger et al., 2013), exhibited a similar
expression pattern in hepatocytes along the porto-central axis
(Figures 1A and S1A). This staining gradient is suggestive of a
role for YAP in the zonation of hepatocytes, which have special-
ized metabolic functions depending on their position in the
liver lobule (Jungermann and Katz, 1989). The zonation program
is thought to be governed by the interplay of the HNF4A
and WNT/b-CATENIN pathways and is characterized by strict
boundaries of expression of key metabolic genes in the pericen-
tral region and periportal regions (e.g., glutamine synthase and
glutaminase 2, respectively) (Benhamouche et al., 2006; Gouge-
let et al., 2014; Torre et al., 2011).
To study the impact of Hippo pathway modulation on liver cell
identity and proliferation, we generated mice with liver-specific
Mst1/Mst2 double-knockout (DKO), Yap deletion (Yap KO),
and DKO combined with hemizygous or homozygous Yap dele-
tion (designated DKO Yap+/ and triple-knockout [TKO] mice,
respectively) via crosses of floxed strains to Albumin-Cre mice.
Necropsy at 7 weeks revealed that DKO mice had massive liver
overgrowth and high levels of hepatocyte proliferation, associ-
ated with upregulation of nuclear and total Yap levels throughout
the hepatocyte compartment and marked expansion of SOX9+
and SOX9 ADCs in the periportal region (Figures 1C, S1B,
and S1C), as previously reported in other Hippo pathway mutant
mouse models (Benhamouche et al., 2010; Lee et al., 2010;
Lu et al., 2010; Yimlamai et al., 2014). In addition, DKO animals
exhibited a striking loss of hepatocyte zonation as reflected by
decreased pericentral expression of glutamine synthase (GS)
and ornithine aminotransferase (OAT) (Figures 1C, 1D, and
S1D). Each abnormality was rescued in DKO Yap+/ and TKO
mice, although the latter exhibited biliary defects, regional hepa-
tocyte necrosis, cholestasis, fibrosis, and swelling of the tissue
as observed in Yap KO livers (Zhang et al., 2010). Notably, in
Yap KO mice, we found expansion of the GS+ domain, such
that several layers of hepatocytes surrounding the central vein,
aswell as scattered cells throughout the lobule, showed aberrant
induction of GS (Figure 1D). These findings link aberrantly
activated YAP to hepatocyte reprogramming downstream of
MST1/MST2 and reveal an unexpected role of basal YAP func-
tion in maintenance of hepatocyte zonation.
Despite the ongoing expansion of ADCs, proliferating cells
with hepatocyte morphology persisted in the DKO liver and ex-
hibited a higher frequency of proliferating cell nuclear antigen
(PCNA) staining than adjacent ADCs (Figure S1C). Together,
these data imply that the response of hepatocytes to activation
of endogenous YAP is distinct depending on their zonal location,
creating a highly proliferative population of dedifferentiated
(GS) pericentral hepatocytes as well as an expanded pool of
ADCs emerging from periportal hepatocytes.
Acute Deregulation of the Hippo Pathway Overrides
Hepatocyte Zonation
We recapitulated the above phenotypes in the setting of acute
deregulation of the Hippo pathway using intravenous injection
of Cre adenovirus to conditionally delete Mst1/Mst2 and Yap inReports 10, 1692–1707, March 17, 2015 ª2015 The Authors 1693
Figure 1. Hippo Signaling Is a Rheostat that Controls Hepatocyte Identity
(A and B) IHC (A) and immunofluorescence (B) of mouse liver in the region of the portal vein (top row) and central vein (middle row), demonstrating nuclear and
cytoplasmic YAP staining in bile ducts (arrow) and periportal hepatocytes, and absence of YAP in the first layer of pericentral hepatocytes. SOX9 shows nuclear
staining in bile ducts andweaker nuclear staining in periportal hepatocytes, whereas it is excluded from the nucleus in pericentral hepatocytes. GS is a pericentral
marker. CK19 is a biliary marker. The schematic representation of the porto-central axis indicates the territories of expression for YAP, SOX9, and GS. Yap KO
liver (bottom row) is a negative control for YAP staining. Insets show magnified periportal or pericentral hepatocytes in (A). Bile duct is indicated by an asterisk in
(B). Scale bars, 20 mm (A) and 50 mm (B).
(C) Gross, histologic, and IHC analyses of livers of the indicated genotypes (Albumin-Cre models). Cross: necrotic region in TKO. Scale bars, 5 mm (gross), 50 mm
(H&E, YAP, PCNA, and SOX9), and 100 mm (GS).
(D) GS staining in pericentral regions. Scale bar, 20 mm.
PV, portal vein; CV, central vein; BD, bile duct; HA, hepatic artery. See also Figure S1.
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adult hepatocytes (designated as the DKOAd, TKOAd, and Yap
KOAd models). An examination at 2 weeks post-injection re-
vealed that DKOAd mice had increased hepatocyte proliferation,
ADC expansion, and reduced pericentral GS expression
compared with wild-type (WT)Ad livers (Figures 2A–2C).
These changes were rescued by Yap ablation (TKOAd and DKO
Yap+/Ad models); moreover, Yap KOAd mice exhibited expan-
sion of the GS+ domain (10.1% ± 0.5% of hepatocytes were
GS+ in WTAd livers versus 16.0% ± 0.9% in Yap KOAd, and
8.0% ± 0.5% in DKOAd; Figure 2C; see Supplemental Experi-
mental Procedures). Thus, YAP serves as a rheostat for
maintaining quiescence and identity in adult hepatocytes. In
particular, activation of YAP overrides the pericentral zonation
program and also directs periportal hepatocytes to dedifferen-
tiate to ADCs, whereas basal levels of Yap are required to
prevent the aberrant induction of a pericentral phenotype in
multiple layers of hepatocytes surrounding the central vein.
We conducted gene-expression profiling at day 8 following
Ad-Cre administration to determine the early transcriptional
changes provoked by Mst1/Mst2 inactivation (WTAd versus
DKOAd). Gene set enrichment analysis (GSEA) revealed that
acute Mst1/Mst2 DKO caused potent inactivation of the hepa-
tocyte differentiation program, with downregulation of hun-
dreds of hepatocyte-specific genes (Figure 2D). Accordingly,
the set of downregulated genes was highly enriched for estab-
lished targets of the master regulators of hepatocyte identity,
HNF4A and FOXA2. Conversely, there was upregulation of
cell-proliferation signatures enriched for E2F target genes
(Figure 2E). Experimentally determined binding sites for
TEAD/TEF-1 were significantly enriched in the promoter ele-
ments of the differentially expressed genes (p < 2.0 3 1014),
as was the consensus TEAD/TEF1 binding motif (Figure S2A),
consistent with TEAD family proteins being the key partners
for YAP in the liver (Liu-Chittenden et al., 2012). We identified
candidate direct YAP targets by integrating the expression
analysis and chromatin immunoprecipitation (ChIP) data for
TEAD binding in hepatic cells (HepG2 cells, ENCODE data-
base; Figure S2B; Table S1). This gene set was highly enriched
for predicted targets of HNF4A and FOXA1, which are master
regulators of hepatocyte differentiation that cooperatively regu-
late many common targets (Figure S2B; Alder et al., 2014;
Bochkis et al., 2012; Li et al., 2012). Notably, YAP has been
shown to act as a switch for enhancer occupancy of HNF4A
and FOXA2 in the liver, preventing expression of mature hepa-
tocyte genes and promoting expression of liver stem cell (hep-
atoblast) genes (Alder et al., 2014). Moreover, deletion of Hnf4a
in the adult liver results in hepatocyte dedifferentiation and the
emergence of SOX9+ ADCs (Saha et al., 2014; Walesky et al.,
2013). These observations suggest a potential mechanism
involving an interplay between activated YAP and an HNF4A/
FOXA2/FOXA1 module for the control of hepatocyte identity
and quiescence in DKO mice.
Yap Status Dictates HCC Cell Differentiation
Phenotypes Downstream of Hippo Inactivation
We next sought to assess the effects of YAP deficiency on the
tumor phenotype caused by Mst1/Mst2 DKO (Lu et al., 2010;
Zhou et al., 2009). To this end, mice were either necropsied atCellserial time points or monitored until signs of poor body condition
necessitated euthanasia, which in all cases was due to the pres-
ence of liver tumors. At 15 weeks, DKO mice had rampant ADC
expansion, whereas DKO Yap+/ and TKO livers showed only a
focal appearance of hepatocyte-like cells staining strongly for
SOX9, and limited or no cells with ADC morphology (Figure 3A).
In addition, TKO and DKO Yap+/mice had a marked extension
in survival as compared with DKO animals (48.1 and 59.4 weeks
versus 23.5 weeks, respectively), as well as a reduced tumor
burden (TKO 11 tumors/mouse; DKO Yap+/ 10 tumors/mouse,
DKO 39 tumors/mouse; Figures 3B and 3C). Immunohistochem-
istry (IHC) confirmed that TKO tumors lacked Yap expression,
indicating that they did not emerge from rare cells that escaped
Yap deletion (Figure 3E, lower panel). Thus, Yap has a central
role in tumorigenesis in the DKO model and even single-copy
Yap ablation greatly delays HCC progression. On the other
hand, results from TKO mice demonstrate that Mst1/Mst2
inactivation can still ultimately drive liver tumorigenesis through
a YAP-independent, albeit less potent, program.
Histopathologic analysis at end stage revealed that the tumors
in each genotype were invasive HCC (Figure 3E). However,
the groups expressed distinct sets of differentiation markers,
with the DKO HCCs staining for SOX9 and lacking both GS
and nuclear b-CATENIN, and the great majority of TKO and
DKO Yap+/ tumors showing the opposite profile (Figures 3D
and 3E). The phenotypes caused by liver-specific inactivation
of Nf2, which are partially due to YAP activation, overlap those
observed in DKO mice (Benhamouche et al., 2010; Yin et al.,
2013; Zhang et al., 2010). An examination of Nf2 KO HCCs
revealed heterogeneous YAP staining in sharply demarcated
regions. Those with higher nuclear and cytoplasmic YAP ex-
pressed SOX9 and lacked GS, whereas those with lower levels
of YAP staining showed a reciprocal pattern (Figure S3A), again
correlating YAP levels and markers of the HCC differentiation
state. Together, these findings suggest a link between YAP-
dependent hepatocyte reprogramming and HCC initiation, and
connect YAP activity to the specific malignant phenotype of
the ensuing tumors.
Therapeutic Efficacy of siRNA-LNPs Targeting YAP
in Advanced HCC
We next explored the functions of YAP in the clinically relevant
setting of maintenance of established tumors. In this regard,
the use of siRNA encapsulated into LNPs (siLNPs), which im-
proves the cellular uptake, stability, and pharmacokinetics
of the siRNA (Whitehead et al., 2009), is an approach to YAP
targeting with clinical potential. Primary HCC is a particularly
plausible cancer context for the use of siRNA-LNP because
the dual blood supply and fenestrated endothelium in the liver
lead to high perfusion, which may facilitate siRNA-LNP delivery.
To test this strategy, we developed protocols to monitor tumor
development in the DKOAd model by ultrasound (US) imaging.
Pilot studies with serial imaging followed by necropsy provided
histologic verification that the lesions detected by US were
invasive HCC (Figure 4A). Subsequently, an additional cohort
was imaged, and animals with comparable tumor burden were
randomized to receive tail-vein injections of siLNPs targeting
YAP or a luciferase (Luc) control (Figure 4B). Mice wereReports 10, 1692–1707, March 17, 2015 ª2015 The Authors 1695
Figure 2. Acute Effect of Hippo Pathway Modulation on Hepatocyte Identity
(A–C) Mice were administered Cre adenovirus intravenously and livers were analyzed 2 weeks later by IHC for YAP, SOX9, PCNA, and GS. The graphs quantify
PCNA (B) and GS (C) staining. n = 3mice in theWT,WTAd, Yap KOAd, and TKOAd groups; 4mice in the DKOYap+/ Ad group; and 5mice in the DKOAd group. Error
bars indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Scale bars, 20 mm (YAP and SOX9) and 50 mm (PCNA and GS).
(D and E) GSEA of mRNA expression data after acute deletion of Mst1/Mst2 in liver. DKO and WT mice were administered Adeno-Cre, and liver mRNA was
isolated after 8 days.
(D) GSEA revealed rapid loss of a broad program of hepatocyte differentiation genes and targets of the master hepatocyte regulators HNF4A and FOXA2.
(legend continued on next page)
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euthanized after 4 and 9 days to assess the acute responses.
Quantitative RT-PCR (qRT-PCR) and IHC revealed progressive
YAP knockdown by siYap-LNPs (Figures 4C–4E and S4A).
At day 4, IHC showed that 45% of tumor nodules had a partial
or complete reduction in YAP protein (Figures 4E and S4A;
defined as % of HCC cells within the nodule staining above
background; see Figure S4B and Supplemental Experimental
Procedures), and by day 9 this figure increased to 73.5% of
nodules (29.4% partial, 44.1% complete; Figures 4D and 4E).
We also observed a coordinate reduction in expression of Ctgf,
an established YAP-TEAD target, as well as of a series of E2F
targets (Figure 4C).
Importantly, siYAP-LNP treatment resulted in a prominent
decrease in tumor cell proliferation that was proportional to
the degree of knockdown at both day 4 and 9, as determined
by KI67 and PCNA staining (Figures 4D, 4F, S4A, and S4B). At
day 9, 25.5% ± 1.6% of HCC cells in siLuc-LNP treated controls
stained for proliferation markers, whereas the rates in the siYAP-
LNP-treated group were 2.9% ± 0.4% and 11.8% ± 1.1% in
nodules with complete or partial Yap knockdown, respectively
(Figures 4D and 4F). There was no evidence of apoptosis as
determined by cleaved caspase-3 staining (Figure S4A). These
findings were corroborated using a second siLNP targeting a
different YAP sequence (siYAP-LNP#2; Figure S4C) and reveal
a critical function of YAP in the proliferation of advanced HCC
in this model.
To identify the transcriptional program underlying YAP-
mediated tumor maintenance, we conducted RNA-sequencing
(RNA-seq) on siLuc- and siYAP-treated tumors following
9 days of treatment. GSEA revealed that YAP silencing caused
potent inactivation of the E2F/cell proliferation pathway (Figures
4G and S4D, left panel). Reciprocally, there was a pronounced
induction of a hepatocyte differentiation signature (Figure 4H,
left panel), including activation of a program of specific pericen-
tral hepatocyte markers (Figure 4H, right panel), and enrichment
of predicted HNF4A targets (Figure S4D, right panel). We inte-
grated the set of genes that were altered by siYAP-LNP treat-
ment in HCCs with ChIP data for TEAD occupancy in liver
cancer cells in order to identify candidate direct YAP/TEAD
target genes in these tumors (see Experimental Procedures).
To gain further insight into transcriptional circuits, we then
searched this YAP/TEAD signature for enrichment of known
binding sites for other transcription factors using the ENCODE
database (Figure S4E; Table S2). In line with our observations
in the DKO liver, the YAP/TEAD signature was greatly enriched
for HNF4 and FOXA1 binding sites, which were ranked first
and second among all transcription factors analyzed, consistent
with the interplay between these factors in dictating the balance
between tumor maintenance and hepatocyte differentiation
(Figure S4E).
A comparison of the day 4 and day 9 time points indicated that
the differentiation markers were gradually induced. At day 4,
multiple HCC nodules with patchy staining for GS and nuclear(E) GSEA showed strong induction of a proliferation gene signature includi
NES, normalized enrichment score; FDR, false-discovery rate. Gene set
(HNF4a_LIVER_SPECIFIC), which is a curated list of liver-specific HNF4A targets
See also Figure S2 and Table S1.
Cellb-CATENIN were observed in siYAP-LNP-treated mice, with
positively stained regions correlating with areas of more com-
plete YAP knockdown (Figure S4F). By day 9, uniform staining
for both markers was frequently observed, coordinated with
loss of SOX9 (Figure 4I). Thus, YAP inhibition in aggressive
HCC causes rapid downregulation of the E2F cell-cycle pathway
and progressive induction of a hepatocyte differentiation pro-
gram associated with upregulation of HNF4/FOXA2/FOXA1
targets and increased activity of the pericentral/b-CATENIN
program.
siYAP-LNPs Induce a Hepatocyte Differentiation
Program in Advanced HCC
Tumor-bearing mice were treated with siRNA-LNPs for 4 weeks
and then euthanized to determine the durability of the response
and uncover any gradual consequences for tumor phenotypes.
Consistent with the profound anti-proliferative effects seen
upon acute YAP knockdown, the siYAP-LNP-treated animals
showed a dramatic reduction in tumor burden as compared
with controls, with marked decreases in the number of HCCs
(9.9 versus 0.5) and their total cross-sectional area (9.2 3 106
mm2 versus 0.753 106 mm2; Figure 5A). Adjacent regions of liver
tissue showed restoration of zonal GS expression and complete
elimination of ADCs (Figure 5B). Remarkably, siYAP-LNP treat-
ment resulted in the replacement of virtually all invasive HCCs
by areas of cells resembling regenerative hepatocyte nodules.
In comparison with the HCCs in control animals, these cells
had a lower nuclear-to-cytoplasmic ratio, lacked mitotic figures,
and showed a reduction in cell-plate thickness (Figure 5C).
Correspondingly, these nodules had low proliferation rates and
showed induction of GS and nuclear b-catenin (Figures 5C and
5D). Thus, sustained YAP inhibition provoked a broad hepato-
cyte differentiation program in established tumors.
The rare remaining HCC foci in siYAP-LNP-treated animals
exhibited persistent YAP expression, suggesting that resistance
arose either from augmented YAP expression or altered uptake
or activity of the siRNA-LNPs (Figure S5A). Importantly, the
treatment regimen was well tolerated. It caused no weight loss
or significant changes in liver function values, and there was a
slight inflammation in periportal areas that was fully resolved
within 2–4 weeks following discontinuation of treatment (Figures
S5B–S5D). These data indicate a central function of YAP in HCC
tumor maintenance in the DKO model and support the appli-
cation of siLNPs targeting YAP to treat advanced HCC. In
addition, these studies provide a proof-of-concept for differen-
tiation therapy as an oncologic approach in the context of an
aggressive epithelial tumor.
YAP-Mediated Control of Proliferative and Hepatic
Differentiation Programs in Primary Tumor Cultures
We used a series of early-passage HCC tumor cultures derived
from independent DKO and TKO mice to examine in vitro
the relationship between Yap activity and proliferation andng established E2F targets. Liver-derived gene sets are indicated in red.
s were obtained from the Molecular Signatures Database, except for
(Saha et al., 2014).
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Figure 3. YAP Suppresses the b-CATENIN Pericentral Program and Drives Invasive HCC Downstream of Mst1/Mst2 DKO
(A) Analysis of the indicated genotypes by H&E and SOX9 staining at 15 weeks. The dedifferentiation of hepatocytes to ADCs caused by Mst1/Mst2 DKO is
blocked by hemizygous or homozygous Yap deletion, although scattered SOX9+ cells are observed by this time point. Insets: high-magnification images of
regions denoted by arrowheads in the main panels. Note differences in the morphology of SOX9+ cells between genotypes. Scale bar, 100 mm.
(B) Left panel: Kaplan-Meier analysis showing the time until animals reached endpoints for disease burden and required euthanasia (see Experimental Pro-
cedures). Median survival is indicated in brackets. n = 16 mice (DKO), 19 mice (DKO Yap+/), and 11 mice (TKO). ****p < 0.0001. Right panels: gross images of
representative livers at sacrifice.
(C) Mean tumor burden at sacrifice. n = 8 mice (DKO), 7 mice (DKO Yap+/), and 7 mice (TKO). Error bars indicate SEM. **p < 0.01.
(D and E) Histologic and IHC analyses of tumors from DKO and TKO mice with end-stage disease.
(D) Quantification of GS staining; n = 4mice per group. Error bars indicate SEM.*p < 0.05 and **p < 0.01. All tumors showed HCC histopathology, although distinct
staining patterns were noted for liver markers.
(E) Top: DKO tumors stained positive for SOX9 and negative for GS and nuclear b-catenin (top), whereas the majority of TKO tumors (bottom) showed the
opposite pattern. All TKO tumors lacked YAP staining. Scale bars, 20 mm (b-catenin), 100 mm (H&E, YAP, and SOX9), and 200 mm (GS).
See also Figure S3.differentiation pathways. Consistent with our in vivo data, DKO
tumor cultures grew more rapidly than TKO cultures and were
characterized by higher expression of multiple E2F-regulated
cell-cycle genes and lower expression of a set of HNF4A targets
involved in specialized hepatocyte functions (Figures 6A and 6B).
Likewise, YAP knockdown in DKO cells caused proliferative1698 Cell Reports 10, 1692–1707, March 17, 2015 ª2015 The Authorarrest without evidence of cell death, whereas TKO cells were
unaffected, demonstrating the specificity of the RNAi (Figures
6C and S6A). The YAP-depleted DKO cells exhibited reduced
expression of E2F target genes and pronounced activation of
the HNF4A gene signature (Figure 6D). Reciprocally, forced
expression of YAP promoted the proliferation of TKO culturess
Figure 4. siLNP-Mediated YAPSilencing Induces Proliferative Arrest and a Pericentral Hepatocyte Differentiation Program in Advanced HCC
(A) Ultrasound (US) detection of a liver tumor in DKOAd at 16 weeks after Adeno-Cre injection. The right panel shows corresponding histology of liver tumors. IVC,
interior vena cava. Scale bar, 100 mm.
(B) Schematic of the therapeutic study. Upon detection of tumors by US imaging, animals were randomized into groups receiving siYAP-LNPs or control siLuc-
LNPs, and euthanized at the indicated time points.
(C) qRT-PCR analysis of tumors isolated after 4 or 9 days of treatment. n = 32 tumors (siLuc), 18 tumors (siYAP 4 days), and 16 tumors (siYAP 9 days). Error bars
indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
(D) Representative IHC staining for YAP and KI67 in HCCs following 9 days of treatment. Note that at 9 days, HCC cells are preferentially targeted by siYAP-LNPs,
whereas all liver cells show knockdown at later time points (see Figure 5C). Scale bars, 20 mm (H&E [right]) and 100 mm (H&E [left], YAP, and KI67).
(E) Quantification of YAP staining in HCC nodules at days 4 and 9. The chart shows the percentage of HCC nodules containing the indicated proportions of
YAP+ tumor cells (black, >75% of cells YAP+; gray, 30%–75%; white, 0%–30%). Note that YAP knockdown efficiency increases from day 4 to day 9.
(legend continued on next page)
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(referred to as TKO-Yap cells), whereas it either slowed or did not
affect the proliferation DKO cells that already harbored high YAP
levels (Figure 6E and data not shown). The TKO-Yap cells
showed a corresponding induction of the E2F target
and suppression of the HNF4A targets (Figure 6F). Finally,
we found that TKO-Yap cells were sensitized to the CDK4
inhibitor PD-0332991 at concentrations that did not affect
TKO-control cells (Figures 6G and S6B). Thus, the role of YAP
in sustaining proliferation and blocking differentiation is recapit-
ulated in cultured HCC cells and points to direct functional
roles for YAP in activating E2F and suppressing HN4A activity
in these tumors.
YAP Activation Is Associated with the Proliferative,
CTNNB1 Wild-Type Subclass of HCC in Humans
Mutations in CTNNB1 define a distinct subtype of HCC with
less aggressive clinical features (Chiang et al., 2008). Since we
observed an inverse correlation between YAP and b-CATENIN
activity in the DKOHCCmodel, our data predict that YAP activa-
tion and CTNNB1 mutations may be associated with different
HCC subtypes. In this regard, it is notable that nuclear b-catenin
staining, which is closely correlated with CTNNB1 mutations,
and nuclear YAP staining showed a strong negative association
in humanHCC specimens (Tao et al., 2014).We sought to extend
these data by using our YAP activity signature to identify HCC
subtypes potentially driven by YAP. We derived this signature
of presumptive direct YAP targets by integrating the set of genes
that were altered by siYAP-LNP treatment in HCCs with ChIP
data for TEAD occupancy in liver cancer cells (see Figure S4E
and Experimental Procedures). To this end, we calculated
enrichment for the YAP activation signature for each of the 111
HCC patients included in our human cohort. Correspondingly,
nearest template prediction (NTP) revealed that the YAP gene-
expression signature had a strong negative correlation with the
CTNNB1mutation signature in this set of human HCCs (Lachen-
mayer et al., 2012; Figure 7A). We corroborated these findings
using three additional, independent HCC classification systems
(Figures S7A–S7C). Moreover, patients who were positive for
the YAP expression signature showed strong enrichment in
the ‘‘proliferation,’’ poor-prognosis gene-expression subtype of
HCC (Figures 7B and S7A; Chiang et al., 2008). In addition,
YAP levels showed a close correlation with an E2F target
gene/proliferation signature across both HCC cell lines and hu-
man specimens (Figures S7D and S7E) Together, these data
suggest that YAP specifically contributes to the growth of an
aggressive CTNNB1 WT subtype of human HCC, and point to
the potential therapeutic value of targeting Yap in these currently
intractable tumors.(F) Quantification of KI67 staining at day 9. The chart shows the percentage of KI67
knockdown. Note that the decrease in KI67 staining correlates with effectiveness
n = 34 tumors from 4 treated mice. Error bars indicate SEM. **p < 0.01, ****p < 0
(G and H) GSEA of differentially expressed genes in response to siYAP-LNPs ve
(G) Cell-cycle genes are repressed.
(H) Left: markers of hepatocyte differentiation are induced. Right: heatmap show
2006). NES, normalized enrichment score; FDR, false-discovery rate.
(I) By day 9, siYAP-LNPs result in loss of SOX9 staining, nuclear translocation of b-
100 mm (H&E [left], YAP, SOX9, and GS).
See also Figure S4 and Table S2.
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We have shown that siRNA-LNP-mediated inhibition of YAP
is an effective therapeutic in a GEM model of advanced
HCC. In response to YAP inactivation, tumor cells underwent
rapid proliferative arrest and subsequently acquired features of
hepatocyte differentiation. These findings demonstrate the po-
tential of YAP as a drug target in HCC and suggest a paradigm
for differentiation therapy in the treatment of this aggressive
epithelial malignancy.
Whereas YAP activation can induce anti-apoptotic genes and
enhance cell survival in multiple contexts, including livers treated
with FAS ligand (Camargo et al., 2007; Zhou et al., 2009), we
found no evidence of cell death upon siYAP-LNP administration
in our HCC model. Rather, we observed inhibition of E2F target
genes and a pronounced reduction in cell proliferation followed
by a gradual activation of a hepatocyte differentiation program,
culminating in the morphologic differentiation of the HCCs
into nodules resembling regenerative hepatocytes. Thus, YAP
inhibition in advanced HCC results in a remarkable reversion
of transformed cells toward a growth-arrested and histopatho-
logically benign phenotype.
Anti-cancer drug development efforts have focused largely on
identifying agents that incite death of the tumor cells. An alterna-
tive approach is to attempt to instruct cancer cells to reactivate
differentiation programs, thereby abrogating self-renewal and a
replicative lifespan. This approach is presently being used suc-
cessfully to treat acute promyelocytic leukemia harboring the
PML/RARA fusion gene, where all-trans retinoic acid and arsenic
trioxide induce terminal differentiation of the leukemic cells into
mature granulocytes and block their self-renewal (de The´ and
Chen, 2010). Whether adult epithelial malignancies retain a
latent capacity to differentiate and whether distinct nodes in
cell regulation can be identified as targets to restore this differen-
tiation potential are key questions for the broader application
of such strategies. Our work provides a proof-of-concept for
this approach in an autochthonous model of aggressive HCC
and identifies YAP as such a targetable node. Since differenti-
ated hepatocytes survive for an extended period of time, it re-
mains to be seen whether a durable response can be attained
via YAP targeting or whether sustained inhibition or combination
therapies are required. Notably, pharmacologic inhibition of YAP
was recently shown to induce differentiation and tumor regres-
sion in embryonal rhabdomyosarcoma xenografts, suggesting
that this approach may extend to multiple cancer types (Trem-
blay et al., 2014).
Our transcriptomic analyses linked YAP activity in the normal
liver and HCC to the negative regulation of targets of HNF4A+HCC cells in different tumor nodules grouped according to the degree of YAP
of YAP knockdown. siLuc-LNP: n = 20 tumors from 3 treated mice; siYAP-LNP:
.0001.
rsus control siLuc-LNPs (day 9).
ing induction of markers specific to pericentral hepatocytes (Braeuning et al.,
CATENIN, and induction of GS. Scale bar, 20 mm (H&E [right] and b-catenin) and
s
Figure 5. siLNP-Mediated YAP Silencing Is an Effective Differentiation Therapy for Advanced HCC
Following detection of tumors by US imaging, DKOAd mice were treated with siRNA-LNPs for 28 days and then euthanized.
(A) Representative gross liver images and H&E-stained sections. Arrows: visible liver tumors; dotted lines: histologically confirmed HCC lesions. The charts show
the number of histologically validated HCC lesions/mouse (left) and tumor area occupied per whole liver cross-section (right; see Experimental Procedures).
n = 9 mice (siLuc-LNP) and 8 mice (siYAP-LNP). Scale bars, 5 mm (gross) and 1 mm (H&E). Error bars indicate SEM. ***p < 0.001, ****p < 0.0001.
(B) The liver parenchyma shows a restoration of zonal GS expression and disappearance of ADCs upon siYAP-LNP treatment. HCC lesions are indicated.
Scale bars, 1 mm (GS) and 50 mm (H&E).
(C) siYAP-LNP treatment results in replacement of invasive HCCs by benign nodules with histopathologic features consistent with differentiation to regenerative
hepatocytes, associated with loss of SOX9, infrequent PCNA staining, focal induction of nuclear b-CATENIN, and strong upregulation of GS. Scale bars, 100 mm
and 20 mm (H&E right panel).
(D) Chart quantifying the proportion of nodules that stained positive for GS. Error bars indicate SEM. ***p < 0.001.
See also Figure S5.
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Figure 6. YAP Positively Regulates an E2F Proliferation Program and Suppresses the Hnf4a Hepatocyte Differentiation Pathway
(A) Left panel: early-passage HCC cultures derived fromDKOmice display a proliferative advantage comparedwith TKO lines. N, number of independent cultures
tested in each group. Right panel: western blot analysis confirming that YAP expression is restricted to the DKO lines.
(B) qRT-PCR analysis shows that DKO lines are characterized by higher basal expression of E2F targets (left panel) and lower expression of HNF4a targets (right
panel). Error bars indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
(C and D) DKO and TKO cell lines were transfected with siRNA against YAP or control siRNA.
(C) Quantification of cell growth data showing that siRNA-mediated YAP knockdown causes proliferative arrest of DKO lines but does not affect TKO cells.
(D) qRT-PCR analysis showing that YAP knockdown in DKO cells results in a significant decrease in the expression of multiple E2F-regulated cell-cycle genes (left
panel) and pronounced activation of HNF4A targets (right panel). Error bars indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
(E–G) TKO cells were transduced with retroviruses expressing human YAP (hYAP) or GFP control.
(legend continued on next page)
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and FOXA2/FOXA1. It is notable that the differentially expressed
genes harboring TEAD binding sites—and thus potential direct
YAP targets—exhibited a striking enrichment for HNF4A and
FOXA1 binding sites (Figure S4E). Although further studies will
be required to resolve the associated transcriptional circuitry,
these results suggest that the reported functions of YAP in
switching the occupancy of HNF4A/FOXA1 from enhancers of
mature hepatocyte genes to those of hepatic progenitor genes
(Schaub et al., 2014) may also be operative in dictating sus-
tained tumorigenic growth versus hepatocyte differentiation in
advanced HCC. Accordingly, deletion of Hnf4a in the adult
mouse liver leads to phenotypes overlapping those observed
upon YAP activation, including loss of hepatocyte identity, prolif-
eration of dedifferentiated hepatocytes, and expansion of ADCs
(Bonzo et al., 2012; Saha et al., 2014; Walesky et al., 2013). We
also found that expression of E2F target genes is positively asso-
ciated with YAP function in vivo (Figures S4D, S7D, and S7E),
consistent with prior work demonstrating cooperative interac-
tions between YAP and E2F in the liver (Ehmer et al., 2014).
Notably, we observed YAP-mediated modulation of HNF4A tar-
gets and E2F targets in vitro using primary HCC cultures, sug-
gesting that the regulatory interactions may be direct (Figure 6).
YAP activity was also associated with SOX9 expression and inhi-
bition of b-CATENIN nuclear translocation, although these path-
ways were not as prominently altered in vitro (data not shown).
Our studies provide a number of insights into the role of
Hippo/YAP in controlling cell fate in the adult liver. In the normal
liver, we found that nuclear YAP was expressed at the highest
levels in the bile ducts and showed a decreasing gradient of
expression along the porto-central axis, with the final row of
pericentral hepatocytes completely lacking YAP expression (Fig-
ures 1A and 1B). Activation of endogenous YAP following acute
Mst1/Mst2 deletion not only resulted in conversion of hepato-
cytes in the periportal area to ADCs but also overrode the zona-
tion program in pericentral hepatocytes, as reflected by the loss
of expression of GS and OAT (Figures 2A and 2C; also see Fig-
ures 1C, 1D, and S1D for the Alb-Cre model). Moreover, acute
deletion of YAP caused aberrant expansion of the GS+ domain
to multiple layers of pericentral hepatocytes (Figures 2A and
2C). Therefore, we have demonstrated an unexpected role for
basal YAP function in maintaining liver zonation, and showed
that the differentiation state of pericentral hepatocytes is sensi-
tive to precise tuning of YAP activity (Figure 7C). Liver zonation
is an intriguing mechanism for regional compartmentalization
of metabolic functions (Jungermann and Katz, 1989; Torre
et al., 2011), and our data establish YAP as a major determinant
of zonal identity with a role opposing that of b-CATENIN, which
activates a pericentral program. It will be of interest to determine
the basis for graded YAP activity within the parenchyma and to
specifically relate YAP function to the control of the diverse
metabolic processes carried out by this organ.(E) YAP expression significantly increases the proliferation of TKO cells (left pane
(F) Forced expression of YAP induces E2F targets (left panel) and inhibits HNF4A
****p < 0.0001.
(G) Treatment with a CDK4/6 inhibitor (PD-0332991, 0.3 mM) impairs the proliferat
TKO control cells (left panel). Error bars indicate SEM. **p < 0.01, ***p < 0.001.
See also Figure S6.
CellAlthough Yap deletion delayed tumorigenesis in DKO mice, it
did not completely prevent the formation of HCC. Rather, all of
the DKO Yap+/ and TKO animals eventually developed inva-
sive HCC. These data are consistent with MST1/MST2 acting
to suppress HCC development through targets in addition to
YAP. It is possible that TAZ, which is expressed in the HCCs
and derivative cell lines (data not shown), partially compensates
for YAP inactivation in this context. Since YAP deficiency elimi-
nated ADCs in TKO mice and resulted in a distinct tumor pheno-
type (well-differentiated histology, b-CATENIN+, GS+, and
SOX9; Figures 3D and 7C), it appears that this secondary
pathway does not fully recapitulate the broad reprogramming
of hepatocyte differentiation induced by YAP.
The link between YAP activity and differentiation status in HCC
appears to be relevant in the corresponding human tumors
as well. Using the transcriptional alterations provoked by YAP
inactivation in our HCC model as a readout for YAP activity,
we found that the YAP signature was negatively correlated
with the CTNNB1 mutant subclass of HCC and positively
correlated with the ‘‘proliferation’’ subclass (Figures 7A, 7B,
and S7A–S7C). These data extend findings from IHC analysis
that showed an inverse correlation between nuclear YAP and
nuclear b-CATENIN (Tao et al., 2014), and point to a molecular
subtype of HCC that may benefit from anti-YAP therapies.
The idea of targeting YAP as a cancer therapy is particularly
compelling due to the clear dosage dependence of its onco-
genic activity. Approaches to inhibit YAP using small molecules
and peptides have been described (Jiao et al., 2014; Liu-Chit-
tenden et al., 2012). Our data suggest that there may be a
clinical path forward using siYAP-LNPs to treat primary HCC.
Importantly, as a genetically targeted therapy, siYAP-LNPs
would be expected to have more specificity and lower toxicity
than most small-molecule inhibitors, and indeed, we observed
mild and reversible side effects in our studies (Figures S5B–
S5D). Finally, siRNA-LNPs can readily be adapted to inhibit




Mice were housed in pathogen-free animal facilities at Massachusetts
General Hospital (MGH). All experiments were conducted under protocol
2005N000148, approved by the Subcommittee on Research Animal Care at
MGH. The following mouse strains were used: Mst1, Mst2Flox, YapFlox, and
Albumin-Cre (Postic and Magnuson, 2000; Schlegelmilch et al., 2011; Zhou
et al., 2009). The Albumin-Cre transgene efficiently deletes floxed sequences
in all liver lineages by 4–6 weeks of age. Mice were maintained on a mixed
genetic background and each genotype was generated from intercrosses
from the same colony. For Adeno-Cre studies, 53 109 pfu of CMV-Cre adeno-
virus resuspended in a final volume of 200 ml PBS was injected into the tail
vein of 6-week-old mice. All mice included in the survival analysis were eutha-
nized when criteria for disease burden were reached (including abdominall).
targets (right panel). Error bars indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
ion of TKO cells expressing YAP (right panel) without affecting GFP-expressing
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Figure 7. TheYAPActivity Signature Is Enriched inHumanHCCSubtypesDefined by a Lack of theCTNNB1Mutation and aProliferation Gene
Profile
(A) Analysis of 111 human HCC specimens reveals an inverse correlation between the CTNNB1 mutation signature and a YAP activation signature.
(B) Using a second HCC classification system (Chiang et al., 2008), the YAP activation signature (YAP+) is positively correlated with the aggressive ‘‘proliferation’’
subclass, whereas absence of the signature (YAP) significantly correlates with the CTNNB1 subclass. Fisher’s exact test was used for statistical analysis.
(C) Model illustrating the impact of Hippo/YAP modulation on liver biology. (i) In normal liver, YAP shows a decreasing gradient of nuclear and cytoplasmic
expression along the porto-central axis. The final layer of hepatocytes adjacent to the central vein completely lacks YAP expression, whereas active
b-catenin and GS are restricted to these cells. (ii) Activation of YAP in hepatocytes results in induction of proliferation-related E2F target genes, down-
regulation of the targets of the HNF4A and FOXA1,2, and loss of pericentral b-CATENIN targets (e.g., GS and OAT), as well as hepatocyte proliferation
throughout the lobule and dedifferentiation of hepatocytes to ADCs in the portal area. The resulting HCCs are poorly differentiated, express SOX9, and lack
nuclear b-CATENIN and its target, GS. Treatment with siYAP-LNPs leads to tumor regression and hepatocyte differentiation. (iii) Yap deletion leads to an
(legend continued on next page)
1704 Cell Reports 10, 1692–1707, March 17, 2015 ª2015 The Authors
distension that impeded movement, loss of >15% of body weight, labored
breathing, and/or abnormal posture).
Human Tumor Specimens
Resected human tumor tissue was collected from the Biorepository Tissue
Bank at the Icahn School of Medicine at Mount Sinai (New York) after approval
by the institutional review board (IRB) committee.
siLNP Formulations
LNPs were formed by mixing equal volumes of lipids dissolved in alcohol
(lipid solution containing a cationic lipid, a helper lipid [cholesterol], a neutral
lipid [DSPC], and a PEG lipid), with siRNA (dissolved in sodium citrate [sodium
chloride buffer], pH 4.0) by an impinging jet process. Following an incubation
period, the solution was concentrated and diafiltered by an ultrafiltration pro-
cess using membranes with amolecular weight cutoff of 100 kDa. The product
was sterile filtered and stored at 4C. The total siRNA was determined by
anion exchange chromatography. The targeted sequences for Yap were
50-TTAAGAAGTATCTTTGACC-30 (siYap-LNP #1) and 50-TTAAGAAAGGGA
TCGGAAC-30 (siYap-LNP #2). A formulation targeting luciferase (siLuc-LNP)
was used as a control. Formulations were intravenously injected (via tail
vein) at 3 mg/kg per injection every other day (for short-term treatment,
i.e., <10 days of treatment) or for 3 consecutive days with a resting period of
2 days between every round of treatment for long-term analysis.
GSEA
We used GSEA (http://www.broadinstitute.org/gsea/index.jsp) of the expres-
sion data to assess enrichment of gene signatures. Depending on the data set,
we used several different methods to rank genes. In the siRNA-LNP studies,
we performed a pairwise GSEA by creating ranked lists of genes using the
log2 ratio of siYAP-LNPs to siLuc-LNPs, and obtained p values by permuting
the gene set. To identify direct target genes (Figures S2B and S4E), we down-
loaded TEADChIP peaks for HEPG2 cells from ENCODE (http://genome.ucsc.
edu/ENCODE/) and generated TEAD-target lists by associating genes with
TEAD peaks using PeakAnalyzer (Salmon-Divon et al., 2010) with the
‘‘closest-TSS’’ routine. We defined YAP signatures by comparing the differen-
tially regulated genes in D8 or D9 and TEAD targets. For transcription factor
enrichment analysis, we utilized the ENCODE ChIP-seq significance tool
(Auerbach et al., 2013). In brief, YAP-TEAD lists for D8 or D9 were uploaded
in the web interface (http://encodeqt.simple-encode.org) and transcription
factor binding sites were detected in the region +5,000 bp to 2,500 bp rela-
tive to the TSS of each gene. We calculated the significance of enrichment of a
transcription factor using the hypergeometric test and corrected for multiple
testing using the Benjamini-Hochberg false-discovery rate (FDR).
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